Get the Stockscreener App
28.96
4.10%
1.14
After Hours:
28.39
-0.57
-1.97%
Mbx Biosciences Inc stock is traded at $28.96, with a volume of 337.18K.
It is up +4.10% in the last 24 hours and down -18.74% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$27.82
Open:
$28.05
24h Volume:
337.18K
Relative Volume:
0.49
Market Cap:
$1.38B
Revenue:
-
Net Income/Loss:
$-86.97M
P/E Ratio:
-11.97
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
+0.91%
1M Performance:
-18.74%
6M Performance:
+67.11%
1Y Performance:
+271.76%
1-Day Range:
$28.05
$29.40
1-Week Range:
$26.84
$29.88
52-Week Range:
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
28.96 | 1.32B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX (NASDAQ: MBX) affiliate files sale notice for 1,061 vested shares - Stock Titan
MBX Biosciences (MBX) Is Down 6.5% After Wider Losses And New Shelf Filings Has The Bull Case Changed? - simplywall.st
Hudson Bay Capital Management LP Purchases New Stake in MBX Biosciences, Inc. $MBX - MarketBeat
Aug Intraday: Can MBX Biosciences Inc keep up with sector leaders2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch - TipRanks
Top MBX Biosciences (MBX) Competitors 2026 - MarketBeat
MBX Biosciences (MBX) CFO John Smither files initial Form 3 - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
MBX Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MBX Biosciences Chief Makes Bold Insider Move With Major Stock Buy - TipRanks
Company (NASDAQ: MBX) Form 144 — 10,000-share sale notice via Fidelity - Stock Titan
MBX Biosciences (NASDAQ:MBX) Shares Gap Up After Insider Buying Activity - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback - simplywall.st
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 By Investing.com - Investing.com India
Hawryluk P. Kent buys MBX Biosciences shares worth $525,662 - Investing.com
MBX Biosciences (NASDAQ:MBX) CEO Buys $525,585.00 in Stock - MarketBeat
MBX Biosciences (MBX) CEO adds 18,500 shares via trust purchase - Stock Titan
MBX Phase 3 Plans And New CBO Sharpen Rare Disease Focus - Yahoo Finance
Baker BROS. Advisors LP Takes $4.86 Million Position in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences completes FDA meeting for Phase 3 trial design - Investing.com Nigeria
Ghisallo Capital Management LLC Takes $669,000 Position in MBX Biosciences, Inc. $MBX - MarketBeat
Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? - MSN
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) - The Globe and Mail
MBX Biosciences Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Citizens reiterates Market Outperform on MBX Biosciences stock - Investing.com Nigeria
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Sahm
Truist reiterates Buy on MBX Biosciences stock, $50 target By Investing.com - Investing.com Australia
Decoding MBX Biosciences Inc (MBX): A Strategic SWOT Insight - GuruFocus
Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026 - Meyka
Truist reiterates Buy on MBX Biosciences stock, $50 target - Investing.com South Africa
MBX Biosciences (NASDAQ: MBX) files $250M ATM sales agreement with Jefferies - Stock Titan
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target - Investing.com UK
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III - Investing.com India
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences : Company OverviewMarch 2026 - marketscreener.com
MBX: Advanced clinical pipeline and raised capital, supporting operations into 2029 - TradingView
MBX Biosciences 10-K: Operating loss $98.1M, Net loss $87.0M — cash runway into 2029 - TradingView
MBX Biosciences (NASDAQ: MBX) outlines precision peptide pipeline - Stock Titan
MBX Biosciences (NASDAQ: MBX) reports 2025 loss and cash runway into 2029 - Stock Titan
Inside MBX Biosciences’ $459M push into monthly obesity and hormone drugs - Stock Titan
MBX: Phase 3 for hypoparathyroidism starts in Q3, with major obesity and PBH data readouts ahead - TradingView
Is MBX Biosciences’ (MBX) Regulatory Win and Leadership Refresh Reframing Its Hypoparathyroidism Strategy? - simplywall.st
Stifel maintains MBX Biosciences (MBX) buy recommendation - MSN
Executives to engage with investors at key biotech events, MBX Biosciences outlines - Traders Union
MBX: FDA-aligned phase 3, strong pipeline, and funding secured for long-acting endocrine therapies - TradingView
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - BioSpace
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):